Skip to content
← Back to browse
OTHER Publication-derived

Generation and Characterization of Patient-Derived Mesothelioma Organoids and Patient-Derived Xenografts (PDX) Models

Source Eltjona et al., 2017 · University Hospital of Novara, Department of Health Sciences · 10.1186/1750-1172-3-34

👤 Rrapaj Eltjona, Renzo Boldorini, Marisa Gariglio ⏱ 180 days 📋 5 phases 🧫 Patient-Derived Mesothelioma Biopsies (Malignant Pleural Mesothelioma)

Abstract

This protocol describes the generation and characterization of three-dimensional patient-derived organoids and patient-derived xenograft (PDX) models from human malignant pleural mesothelioma (MPM) biopsies. Human mesothelioma tissue fragments obtained via thoracoscopic biopsy are used to develop in vitro 3D organoid cultures and in vivo PDX models in immunodeficient mice, providing platforms for drug sensitivity testing, molecular characterization, and investigation of HMGB1 protein as a prognostic biomarker.

Cell source
Patient-Derived Mesothelioma Biopsies (Malignant Pleural Mesothelioma)
Application
Disease modeling, Drug screening, Biomarker validation

Protocol overview

31 steps across 5 phases

Sample Collection and Preparation Day 0
  1. 1 Obtain fresh mesothelioma biopsies or tumor fragments
  2. 2 Transport and initial tissue assessment
  3. 3 Divide tissue for parallel in vitro and in vivo models
In Vitro Organoid Generation and Culture Days 0-7
  1. 1 Prepare mesothelioma tissue for dissociation
  2. 2 Enzymatic and mechanical dissociation of tumor tissue
  3. 3 Assess cell viability and count
  4. 4 Prepare organoid culture matrix and medium
  5. 5 Establish 3D organoid cultures
  6. 6 Culture organoids with media changes
  7. 7 Characterize organoid morphology
  8. 8 Immunofluorescence characterization of organoid markers
  9. 9 Passage organoids in vitro
In Vivo Patient-Derived Xenograft (PDX) Model Development Days 0-180
  1. 1 Prepare immunodeficient mice for implantation
  2. 2 Prepare tumor tissue for implantation
  3. 3 Surgical implantation of tumor tissue
  4. 4 Monitor tumor growth and measure dimensions
  5. 5 Conduct serial passages of PDX tumors
  6. 6 Immunophenotyping of PDX tumors
  7. 7 Perform histopathological and immunohistochemical analysis of PDX tumors
  8. 8 Bank tumor tissue and establish cryopreservation
Drug Sensitivity Testing and Biomarker Studies Days 14-90
  1. 1 Prepare organoid and PDX-derived cell suspensions for drug testing
  2. 2 Establish baseline growth kinetics and proliferation assay
  3. 3 Conduct dose-response drug sensitivity studies
  4. 4 Evaluate HMGB1 expression in organoids and PDX tumors
  5. 5 Test HMGB1-targeting therapeutic agents
Molecular Characterization and Data Analysis Days 90-180
  1. 1 Extract RNA from organoids and PDX tumors
  2. 2 Perform reverse transcription (RT) for cDNA synthesis
  3. 3 Perform RT-PCR for HMGB1 gene expression analysis
  4. 4 Quantify HMGB1 mRNA expression by qRT-PCR
  5. 5 Perform statistical analysis of data
  6. 6 Compare organoid/PDX characteristics with original patient tumor

Full SOP

🔬

Create a free account to access this protocol

Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.

Create free account

Already registered? Log in

Attribution

This SOP was authored by Organthis based on the published method in Eltjona et al., 2017. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.

This wording is awaiting legal review.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?
Use this protocol in your therapeutic or diagnostic pipeline.
Request Commercial Licence